Brief: Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma
09/07/2024 14:22
July 9 (Reuters) - Intensity Therapeutics Inc INTS.O :
* INTENSITY THERAPEUTICS, INC. ANNOUNCES FIRST PATIENT DOSED
IN
ITS GLOBAL RANDOMIZED, PHASE 3 STUDY (INVINCIBLE-3) IN
METASTATIC SOFT TISSUE SARCOMA
Source text for Eikon: ID:nPn3GkQL2a
Further company coverage: INTS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Intensity Therapeutics
See all newsIntensity Therapeutics Q2 net loss widens as R&D costs rise
Brief: Intensity Therapeutics Q2 Operating Income USD -3.084 Million
Intensity Therapeutics Q1 net loss narrows on lower R&D costs
Brief: Intensity Therapeutics Q1 Operating Income USD -2.526 Million
Brief: Intensity Therapeutics Inc - Increases ATM Offering Capacity To $60 Million On March 23, 2026 - SEC Filing